2024 Asia Conference on Lung Cancer (ACLC) - Poster & ePosters-EP02.14

EP02.14 - Yintao Li

Pdf Summary

The study titled "Treatment options for tumor progression after initial immunotherapy in advanced non-small cell lung cancer: a real-world study" by authors Ying Li, Junfeng Zhao, and Yintao Li from Shandong Cancer Hospital examines treatment strategies for advanced non-small cell lung cancer (NSCLC) patients who experience tumor progression after initial immunotherapy.<br /><br />This retrospective study included 507 patients with NSCLC, who were divided into two groups: those receiving additional combination therapy involving immunotherapy post-progression (Immuno-combination group) and those who did not receive further immunotherapy (No-immuno group). The researchers evaluated progression-free survival (PFS) and overall survival (OS) across these groups.<br /><br />The study found that patients in the Immuno-combination group had significantly better PFS and OS outcomes compared to the No-immuno group. Specifically, at six months, the PFS rate was 60.6% in the Immuno-combination group versus 25.3% in the No-immuno group, and at 12 months, the OS rate was 69.4% versus 22.3%.<br /><br />Subgroup analysis revealed that patients who received Immuno-antiangiogenic therapy had better PFS and OS outcomes compared to those who received Immuno-chemotherapy. At 6 months, the PFS rate was 71.5% for the Immuno-antiangiogenic group versus 51.3% for the Immuno-chemotherapy group, while the 18-month OS rates were 48.7% and 33.3%, respectively.<br /><br />The study concludes with the development of a predictive nomogram based on imaging histological features, radiotherapy dosimetric parameters, and clinicopathological features, which can be a practical tool for predicting recurrence in NSCLC patients treated with ICI-TRT (immune checkpoint inhibitor therapy-radiotherapy combination).<br /><br />These findings suggest that continuing or modifying immunotherapy after tumor progression can be beneficial for NSCLC patients, with Immuno-antiangiogenic therapy showing particularly promising results.

Keywords

non-small cell lung cancer

NSCLC

immunotherapy

tumor progression

Immuno-combination

progression-free survival

overall survival

Immuno-antiangiogenic therapy

predictive nomogram

real-world study